Skye Bioscience's nimacimab fell short of investor and company expectations, but showed encouraging weight-loss results when ...
Amgen will offer its lipid-lowering drug Repatha directly to patients for $239 per month, representing a nearly 60% reduction ...
Of the three highest bidders, Pfizer’s purchase proposal for Metsera was the lowest, regulatory documents reveal. The New ...
A new survey from CRB showed that most manufacturing initiatives in the U.S. made in response to tariffs are coming from Big ...
Cell and gene therapy experts question where the FDA designation fits in an environment that features a range of intersecting ...
From Commissioner’s National Priority Vouchers to a push to move away from animal studies to new guidances for oncology and ...
AstraZeneca has invested heavily in AI, primarily through collaborations, including an up to $5.3 billion partnership with ...
Rocket Pharmaceuticals' strategic realignment initiative in July pulled funding from fanca-cel, which the biotech was ...
The centerpiece of the collaboration is the gene editor ABO-101, being developed for primary hyperoxaluria type 1, a rare ...
A new group of CDC advisors voted last month to separate the chickenpox vaccine from the measles, mumps, rubella components ...
The hold was placed earlier this year when the FDA asked for more preclinical data, but the agency was slow to respond due to ...
This latest FDA program aims to provide speedier reviews for generic drugmakers who produce their products in the U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback